Emerging roles of liposomal bupivacaine in anesthesia practice

Obaid Malik, Alan D Kaye, Aaron Kaye, Kumar Belani, Richard D Urman, Obaid Malik, Alan D Kaye, Aaron Kaye, Kumar Belani, Richard D Urman

Abstract

Despite advances in drug technology and improvements in technology, including peripheral nerve catheters and ultrasound, postoperative pain is still a significant problem in the clinical setting worldwide. Postoperative pain can have a critical negative impact with regard to physiological consequences to the body and therefore, the role of liposomal bupivacaine as an extended release bupivacaine with approximately 72 h of duration may have far-reaching and significant impact in clinical practice. Liposomal bupivacaine has a DepoFoam multivesicular liposome technology with particle suspension in an isotonic aqueous solution and consists of tiny lipid-based particles, which contain discrete water-filled chambers dispersed through a lipid matrix. Other advantages include a reduction in opioid consumption, while not requiring a catheter or any other device, as well as easy dilution with saline. This review summarizes current research with this novel agent in postsurgical pain, and discusses potential roles in chronic pain states. Further studies are warranted for its use in epidural and intrathecal administration. Moreover, this review will explore the expansion of liposomal bupivacaine's current clinical role.

Keywords: Analgesia; Exparel; liposomal bupivacaine; nerve blocks; postoperative pain.

Conflict of interest statement

There are no conflicts of interest.

References

    1. Kaye AD, Jones MR, Kaye AM, Ripoll JG, Galan V, Beakley BD, et al. Prescription Opioid Abuse in Chronic Pain: An Updated Review of Opioid Abuse Predictors and Strategies to Curb Opioid Abuse: Part 1. Pain Physician. 2017;20(2S):S93–S109.
    1. Kaye AD, Jones MR, Kaye AM, Ripoll JG, Jones DE, Galan V, et al. Prescription Opioid Abuse in Chronic Pain: An Updated Review of Opioid Abuse Predictors and Strategies to Curb Opioid Abuse (Part 2) Pain Physician. 2017;20(2S):S111–S133.
    1. Rice DC, Cata JP, Mena GE, Rodriguez-Restrepo A, Correa AM, Mehran RJ. Posterior intercostal nerve block with liposomal bupivacaine: An alternative to thoracic epidural analgesia. Ann Thorac Surg. 2015;99:1953–60.
    1. Woodcock J. Attn: David Stack. Chief Executive Officer & Chairman. Letter to Pacira Pharmaceuticals, Inc. 2015
    1. Liu SS, Buvanendran A, Rathmell JP, Sawhney M, Bae JJ, Moric M, et al. Predictors for moderate to severe acute postoperative pain after total hip and knee replacement. Int Orthop. 2012;36:2261–7.
    1. Tong YC, Kaye AD, Urman RD. Liposomal bupivacaine and clinical outcomes. Best Pract Res Clin Anaesthesiol. 2014;28:15–27.
    1. King CH, Beutler SS, Kaye AD, Urman RD. Pharmacologic Properties of Novel Local Anesthetic Agents in Anesthesia Practice. Anesthesiol Clin. 2017;35:315–25.
    1. Barash PG, Cullen BF, Stoelting KR, Cahalan M, Stock C, Ortega R. Clinical anesthesiology. In: Lin Y, Liu SS, editors. Local Anesthetics. 7th ed. New York: Lippincott Williams; 2013. pp. 561–82.
    1. Ilfeld BM, Viscusi ER, Hadzic A, Minkowitz HS, Morren MD, Lookabaugh J, et al. Safety and side effect profile of liposome bupivacaine (Exparel) in peripheral nerve blocks. Reg Anesth Pain Med. 2015;40:572–82.
    1. Ye Q, Asherman J, Stevenson M, Brownson E, Katre NV. DepoFoam technology: A vehicle for controlled delivery of protein and peptide drugs. J Control Release. 2000;64:155–66.
    1. Angst MS, Drover DR. Pharmacology of drugs formulated with DepoFoam™: A sustained release drug delivery system for parenteral administration using multivesicular liposome technology. Clin Pharmacokinet. 2006;45:1153–76.
    1. Boogaerts J, Declercq A, Lafont N, Benameur H, Akodad EM, Dupont JC, et al. Toxicity of bupivacaine encapsulated into liposomes and injected intravenously: Comparison with plain solutions. Anesth Analg. 1993;76:553–5.
    1. Naseem A, Harada T, Wang D, Arezina R, Lorch U, Onel E, et al. Bupivacaine extended release liposome injection does not prolong QTc interval in a thorough QT/QTc study in healthy volunteers. J Clin Pharmacol. 2012;52:1441–7.
    1. Pacira Pharmaceuticals, Inc. Exparel (bupivicaine liposomal injectable suspension) [prescribing information] San Diego, CA: Pacira Pharmaceuticals, Inc; 2012. [Web 11 April 2013]. Available from: .
    1. Bramlett K, Onel E, Viscusi ER, Jones K. A randomized, double-blind, dose-ranging study comparing wound infiltration of DepoFoam bupivacaine, an extended-release liposomal bupivacaine, to bupivacaine HCl for postsurgical analgesia in total knee arthroplasty. Knee. 2012;19:530–6.
    1. Smoot JD, Bergese SD, Onel E, Williams HT, Hedden W. The efficacy and safety of DepoFoam bupivacaine in patients undergoing bilateral, cosmetic, submuscular augmentation mammaplasty: A randomized, double-blind, active-control study. Aesthet Surg J. 2012;32:69–76.
    1. Golf M, Daniels SE, Onel E. A phase 3, randomized, placebo-controlled trial of DepoFoam ® bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy. Adv Ther. 2011;28:776–88.
    1. Gorfine SR, Onel E, Patou G, Krivokapic ZV. Bupivacaine extended-release liposome injection for prolonged postsurgical analgesia in patients undergoing hemorrhoidectomy: A multicenter, randomized, double-blind, placebo-controlled trial. Dis Colon Rectum. 2011;54:1552–9.
    1. Cohen SM. Extended pain relief trial utilizing infiltration of Exparel(®), a long-acting multivesicular liposome formulation of bupivacaine: A phase IV health economic trial in adult patients undergoing open colectomy. J Pain Res. 2012;5:567–72.
    1. Lissauer J, Mancuso K, Merritt C, Prabhakar A, Kaye AD, Urman RD. Evolution of the transversus abdominis plane block and its role in postoperative analgesia. Best Pract Res Clin Anaesthesiol. 2014;28:117–26.
    1. Keller DS, Tahilramani RN, Flores-Gonzalez JR, Ibarra S, Haas EM. Pilot study of a novel pain management strategy: Evaluating the impact on patient outcomes. Surg Endosc. 2015 Aug 15; [Epub ahead of print]
    1. Hutchins J, Delaney D, Vogel RI, Ghebre RG, Downs LS, Jr, Carson L, et al. Ultrasound guided subcostal transversus abdominis plane (TAP) infiltration with liposomal bupivacaine for patients undergoing robotic assisted hysterectomy: A prospective randomized controlled study. Gynecol Oncol. 2015;138:609–13.
    1. Gasanova I, Alexander J, Ogunnaike B, Hamid C, Rogers D, Minhajuddin A, et al. Transversus abdominis plane block versus surgical site infiltration for pain management after open total abdominal hysterectomy. Anesth Analg. 2015;121:1383–8.
    1. Ayad S, Babazade R, Elsharkawy H, Nadar V, Lokhande C, Makarova N, et al. Comparison of transversus abdominis plan infiltration with liposomal bupivacaine versus continuous epidural analgesia versus intravenous opioid analgesia. PLoS One. 2016;11(4)
    1. Barrington JW, Halaszynski TM, Sinatra RS Expert Working Group on Anesthesia and Orthopaedics Critical Issues in Hip and Knee Replacement Arthroplasty FT. Perioperative pain management in hip and knee replacement surgery. Am J Orthop (Belle Mead NJ) 2014;43(4 Suppl):S1–16.
    1. Boogaerts JG, Lafont ND, Declercq AG, Luo HC, Gravet ET, Bianchi JA, et al. Epidural administration of liposome-associated bupivacaine for the management of postsurgical pain: A first study. J Clin Anesth. 1994;6:315–20.
    1. Viscusi ER, Candiotti KA, Onel E, Morren M, Ludbrook GL. The pharmacokinetics and pharmacodynamics of liposome bupivacaine administered via a single epidural injection to healthy volunteers. Reg Anesth Pain Med. 2012;37:616–22.
    1. Ilfeld BM. Liposome bupivacaine in peripheral nerve blocks and epidural injections to manage postoperative pain. Expert Opin Pharmacother. 2013;14:2421–31.
    1. MacVicar J, Borowczyk JM, MacVicar AM, Loughnan BM, Bogduk N. Cervical medial branch radiofrequency neurotomy in New Zealand. Pain Med. 2012;13:647–54.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren